Latest Manufacturing Capacity Expansion News

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Australian Strategic Materials reports a 70% surge in NdFeB alloy production, installs pilot heavy rare earth furnace, and progresses its acquisition by Energy Fuels with regulatory approvals underway.

IperionX has transitioned its Virginia titanium operations to continuous 24/7 production, ramping proprietary HAMR™ titanium powder output to 4.2 metric tons in March and targeting 200 tons per annum by the end of 2026. Alongside manufacturing capacity expansions and strong U.S. Department of War backing, the company advances its critical minerals project in Tennessee.

DGL Group reported a 5.8% revenue decline to $225.2 million in H1 FY26, weighed down by audit qualifications, ERP rollout delays, and one-off impairments. Despite these headwinds, the company cut net debt by $16.4 million and advanced strategic site consolidations and new facility investments.

AML3D has successfully commissioned a large-scale ARCEMY X 6700 metal 3D printer at US defence supplier FasTech, completing a $1.7 million order and signalling a strategic expansion in the US industrial manufacturing market.

Amaero Ltd reported a 470% revenue surge to $3.8 million for FY2025, driven by expanded production capacity and exclusive supply deals, while continuing to invest heavily in infrastructure and operations, resulting in a $24.4 million loss.

HITIQ Ltd has launched its PROTEQT smart mouthguard for grassroots sports, secured a five-year exclusive global partnership with Shock Doctor, and raised $1.9 million to fund manufacturing and market growth.

Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.